Aspirin for Cardiovascular Prevention

Aspirin's effect on cardiovascular events is one of the most thoroughly characterized phenomena in medicine. The 2002 Antithrombotic Trialists' Collaboration meta-analysis (135,000 patients across 195 trials) established that aspirin in patients with established cardiovascular disease reduces serious vascular events by about 22% — including a 25% reduction in non-fatal MI, 25% reduction in non-fatal stroke, and 17% reduction in vascular death. That secondary-prevention benefit has not been seriously questioned in two decades. What changed dramatically between 2018 and 2022 was the primary-prevention picture: three large modern trials (ARRIVE, ASCEND, ASPREE) found that in adults without established cardiovascular disease, the bleeding harms roughly equal or exceed the thrombotic benefits, leading the USPSTF to substantially restrict its primary-prevention recommendation. This page walks through the mechanism, the trials, and the resulting modern indication boundaries.

Table of Contents

  1. Mechanism: Irreversible COX-1 Acetylation in Platelets
  2. Secondary Prevention: The Uncontroversial Indication
  3. Acute MI and Acute Ischemic Stroke
  4. Primary Prevention: The Old Picture (Pre-2018)
  5. Primary Prevention: The 2018-2022 Reversal
  6. Current USPSTF Guidance (2022)
  7. Dual Antiplatelet Therapy (DAPT) Era
  8. Peripheral Arterial Disease and Carotid Stenosis
  9. Special Populations: Diabetes, CKD, Atrial Fibrillation
  10. Key Research Papers
  11. Connections

Mechanism: Irreversible COX-1 Acetylation in Platelets

The biochemistry that drives aspirin's cardiovascular benefit was elucidated in stages between 1971 and 1985. John Vane's 1971 Nature New Biology paper (PMID 5284360) showed that aspirin inhibits prostaglandin synthesis — work that won the 1982 Nobel Prize. In 1975, Roth and Majerus (PMID 1206094) identified the molecular event: aspirin transfers its acetyl group to a serine residue at position 529 of cyclooxygenase-1 (COX-1), permanently inactivating the enzyme. The transfer is covalent and irreversible; the enzyme cannot recover its function. Only synthesis of new enzyme protein restores activity.

This irreversibility produces aspirin's most clinically valuable property — selectivity for platelets. Platelets are anucleate cell fragments derived from megakaryocytes; they cannot synthesize new protein. A single 75-100 mg dose of aspirin acetylates the COX-1 in essentially all circulating platelets within 30-60 minutes, abolishing their ability to produce thromboxane A2 for the rest of their 7-10 day lifespan. The endothelium, by contrast, is fully nucleated and recovers its COX activity (and thus its prostacyclin production) within hours. Because thromboxane A2 promotes platelet aggregation and vasoconstriction while prostacyclin opposes both, the net effect is a sustained, near-pure antithrombotic effect.

The downstream pathophysiology is the central reason aspirin works. Acute coronary syndromes (unstable angina, NSTEMI, STEMI) and most ischemic strokes share a common final event: rupture or erosion of an atherosclerotic plaque exposes the prothrombogenic subendothelial collagen and tissue factor to circulating blood. Platelets adhere via glycoprotein Ib-IX-V to von Willebrand factor, activate, release thromboxane A2 and ADP, recruit additional platelets, and form an occlusive thrombus. Aspirin abolishes the thromboxane-A2-driven amplification step, so the resulting thrombus is smaller and more likely to be non-occlusive. This is why aspirin reduces acute coronary events and ischemic strokes but has a much smaller effect on hemorrhagic events.

Back to Table of Contents

Secondary Prevention: The Uncontroversial Indication

Secondary prevention — aspirin in patients who have already had a myocardial infarction, ischemic stroke, transient ischemic attack, coronary stent placement, coronary artery bypass graft, peripheral arterial revascularization, or established atherosclerotic cardiovascular disease — is the strongest and least controversial aspirin indication. The 2002 Antithrombotic Trialists' Collaboration (ATT) meta-analysis (PMID 12096097) pooled 195 secondary-prevention trials enrolling more than 135,000 patients. The results:

  1. 22% relative reduction in serious vascular events (non-fatal MI + non-fatal stroke + vascular death).
  2. 25% relative reduction in non-fatal MI.
  3. 25% relative reduction in non-fatal stroke.
  4. 17% relative reduction in vascular death.
  5. Absolute event reduction of approximately 36 events prevented per 1000 patients treated for 2 years after recent MI; 38 events per 1000 after stroke or TIA.

These numbers are remarkable both for their magnitude and for the breadth of clinical settings in which they apply — the benefit was consistent across all major secondary-prevention subgroups. Importantly, the benefit appears largely saturated at low doses; trials directly comparing 75-150 mg with higher doses (325 mg or above) have shown no incremental benefit but increased bleeding. This was definitively settled in the modern era by the ADAPTABLE trial (PMID 33999547), which compared 81 mg vs 325 mg in 15,076 patients with established atherosclerotic cardiovascular disease and found no difference in cardiovascular events or major bleeding at a median 26 months of follow-up. See the Low Dose vs Full Dose deep-dive for the dosing implications.

Secondary prevention is recommended indefinitely in the absence of major bleeding, severe thrombocytopenia, or new contraindication. All major guidelines (ACC/AHA, ESC, AHA/ASA for stroke) recommend daily low-dose aspirin (75-100 mg) for life unless contraindicated.

Back to Table of Contents

Acute MI and Acute Ischemic Stroke

The single most influential aspirin trial in cardiovascular medicine is ISIS-2 (Second International Study of Infarct Survival), published in The Lancet in 1988 (PMID 2899772). ISIS-2 was a 2×2 factorial trial of streptokinase and aspirin in 17,187 patients presenting within 24 hours of suspected acute MI. Aspirin alone (162.5 mg per day for 1 month) reduced 5-week vascular mortality by 23% (9.4% vs 11.8%), and the combination of aspirin plus streptokinase reduced it by 42% compared with placebo. The aspirin benefit alone was equivalent in magnitude to the thrombolytic benefit. The protective effect was sustained at 10-year follow-up.

The clinical translation was immediate: a 162.5 to 325 mg chewable aspirin (chewed, not swallowed whole, to accelerate absorption through the buccal mucosa) is given as soon as acute MI is suspected, before EKG, troponin, or any further workup. Every minute of delay translates to additional myocardial necrosis. The benefit is so large and the cost so low that aspirin is now considered an EMS-administered first-line intervention in suspected acute coronary syndrome. The same recommendation applies in suspected acute ischemic stroke: aspirin 160-300 mg within 48 hours reduces death and dependency by about 1% absolute, equivalent to preventing about 9 deaths or recurrent strokes per 1000 patients treated (Chinese Acute Stroke Trial and International Stroke Trial, 1997).

The acute-MI dose (162.5 to 325 mg, chewable) is higher than the chronic prevention dose because the goal is to achieve rapid, complete platelet COX-1 inhibition, not steady-state antiplatelet effect. Chewable formulations are absorbed faster than enteric-coated tablets; one of the dangerous misconceptions in lay first-aid advice is that enteric-coated tablets are appropriate for suspected MI — they delay therapeutic platelet inhibition by 1-2 hours.

Back to Table of Contents

Primary Prevention: The Old Picture (Pre-2018)

Primary prevention is the question of whether to give aspirin to patients who have not had a cardiovascular event. The historical evidence base came from a handful of trials run between the 1980s and 2010s. The Physicians' Health Study (PMID 2664509) in 1989 was the seminal trial — 22,071 male U.S. physicians aged 40-84, randomized to 325 mg every other day or placebo. The trial was stopped early because aspirin reduced first MI by 44%. This single result drove a generation of primary-prevention recommendations.

The 2005 Women's Health Study (PMID 15753114) randomized 39,876 healthy women aged 45+ to 100 mg every other day or placebo for 10 years. Unlike the Physicians' Health Study, it found no reduction in MI but a 17% reduction in stroke, mostly driven by ischemic stroke reduction in women over 65. This sex difference was unexpected and is still incompletely explained.

The 2009 USPSTF recommendation, based on these older trials and modeling work, recommended aspirin for primary prevention in men aged 45-79 when the MI risk reduction outweighed GI bleeding risk, and in women aged 55-79 when the stroke risk reduction outweighed GI bleeding risk. The 2016 USPSTF recommendation expanded this to suggest aspirin for adults 50-59 with 10-year ASCVD risk ≥10%, willing to take aspirin for at least 10 years, and at low bleeding risk — partly motivated by the colorectal cancer benefit emerging from the Rothwell pooled analyses (see the Colorectal Cancer Risk deep-dive).

Back to Table of Contents

Primary Prevention: The 2018-2022 Reversal

Three large modern primary-prevention trials published in 2018 dramatically changed the picture. All three used contemporary background medical therapy (statins were widely used, blood pressure control was tighter, smoking rates were lower — reducing baseline cardiovascular event rates and shifting the bleeding-benefit balance).

  1. ARRIVE (PMID 30158069) — 12,546 adults at moderate cardiovascular risk randomized to 100 mg aspirin daily or placebo, followed 5 years. No reduction in the primary composite cardiovascular endpoint (hazard ratio 0.96, 95% CI 0.81-1.13). GI bleeding doubled (0.97% vs 0.46%).
  2. ASCEND (PMID 30146931) — 15,480 adults with diabetes but no established cardiovascular disease, randomized to 100 mg aspirin or placebo, followed 7.4 years. Serious vascular events reduced by 12% (8.5% vs 9.6%), but major bleeding increased by 29% (4.1% vs 3.2%) — absolute benefit and absolute harm essentially cancelled.
  3. ASPREE (PMID 30221597, PMID 30221596) — 19,114 healthy adults aged 70+ (or 65+ if Black/Hispanic), randomized to 100 mg aspirin or placebo, followed 4.7 years. No reduction in cardiovascular disease or disability-free survival, but a 38% increase in major bleeding and (unexpectedly) a 14% increase in all-cause mortality, driven by cancer-related deaths.

The ASPREE all-cause mortality signal in particular was unexpected and remains incompletely understood. The cancer-mortality signal may reflect the short follow-up duration (the Rothwell pooled analyses suggest aspirin cancer benefit requires 5-10 years of latency, and ASPREE's 4.7-year follow-up may have captured only the bleeding-associated cancer-death risk without the cancer-prevention benefit yet emerging). Subsequent extended follow-up of ASPREE is ongoing.

Back to Table of Contents

Current USPSTF Guidance (2022)

The USPSTF reissued its aspirin primary-prevention recommendation in April 2022 (PMID 35471505), substantially restricting prior guidance:

  1. Adults aged 40-59 with a 10-year cardiovascular risk ≥10%: small net benefit, individualize the decision (Grade C). The decision should consider patient preferences, bleeding risk factors (prior GI bleed, peptic ulcer disease, NSAID use, anticoagulant use, thrombocytopenia, recent surgery), and remaining life expectancy. Patients who are likely to live long enough to accrue the cancer-prevention benefit (which requires 10+ years) and have low bleeding risk get the most net benefit.
  2. Adults aged 60 and over: do not initiate (Grade D). Net harm in this age group due to higher bleeding risk and uncertain benefit.
  3. The recommendation does not apply to patients with established cardiovascular disease — secondary prevention is governed by separate guidelines and remains a Class I recommendation.

The 2019 ACC/AHA primary-prevention guideline (PMID 30894318) reached a similar conclusion: low-dose aspirin (75-100 mg) "might be considered for primary prevention" in select adults aged 40-70 at higher CV risk and not at increased bleeding risk (Class IIb), and "should not be administered on a routine basis" in adults over 70 or in adults of any age at increased bleeding risk (Class III: Harm).

Patients already taking aspirin for primary prevention before 2018 face a separate question. The general recommendation is that abrupt cessation may transiently increase cardiovascular event risk (the "aspirin withdrawal" rebound phenomenon), so any decision to stop should be made with the prescribing clinician, balancing patient-specific bleeding risk against cardiovascular risk.

Back to Table of Contents

Dual Antiplatelet Therapy (DAPT) Era

Aspirin is rarely used alone in modern interventional cardiology. After percutaneous coronary intervention with stent placement, after acute coronary syndrome, or in the early post-stroke period, patients typically receive dual antiplatelet therapy (DAPT) — aspirin plus a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel).

The CURE trial (PMID 11519503) established the foundation: 12,562 patients with non-ST-elevation acute coronary syndrome randomized to aspirin alone or aspirin plus clopidogrel for 3-12 months. The combination reduced cardiovascular death, MI, or stroke by 20% (9.3% vs 11.4%), at the cost of a 38% increase in major bleeding (3.7% vs 2.7%).

CAPRIE (PMID 8918275), a separate large trial, compared aspirin (325 mg) alone with clopidogrel (75 mg) alone as monotherapy for atherothrombotic disease prevention. Clopidogrel was marginally more effective (8.7% relative risk reduction over aspirin) but more expensive and required a loading dose. For most chronic-phase patients, aspirin monotherapy remains the default antiplatelet agent, with the P2Y12 inhibitor added during the high-risk window after stent or acute event.

Current durations of DAPT depend on the indication (3-12 months after drug-eluting stent in stable CAD; 12 months minimum after acute coronary syndrome with possible extension based on bleeding/ischemic balance). After DAPT discontinuation, aspirin alone continues indefinitely.

Back to Table of Contents

Peripheral Arterial Disease and Carotid Stenosis

In symptomatic peripheral arterial disease (claudication, prior peripheral revascularization), aspirin is recommended as standard secondary-prevention therapy. The benefit is modest in trials of asymptomatic peripheral arterial disease (POPADAD, AAA trials), reinforcing that "secondary prevention" should be defined by symptomatic vascular disease rather than imaging findings alone.

In carotid artery stenosis, aspirin is standard secondary-prevention therapy after carotid endarterectomy or carotid stenting. For asymptomatic carotid stenosis without prior stroke/TIA, the indication is less clear — treatment decisions integrate the degree of stenosis, plaque morphology, and overall cardiovascular risk.

Back to Table of Contents

Special Populations: Diabetes, CKD, Atrial Fibrillation

Diabetes — ASCEND (PMID 30146931) settled the long-running debate. Aspirin in adults with diabetes but without established cardiovascular disease produces benefit (~12% reduction in serious vascular events) that is almost exactly cancelled by increased major bleeding (~29% increase). The 2019 ADA Standards of Care recommend individualization, with aspirin "considered" for primary prevention in diabetes patients with elevated cardiovascular risk and not at increased bleeding risk.

Chronic kidney disease — CKD increases both ischemic and bleeding risk. The net effect of aspirin in advanced CKD (stage 4-5) is uncertain; the limited trial data suggest the bleeding harm may exceed the benefit. Patients on hemodialysis have additional bleeding considerations.

Atrial fibrillation — aspirin is no longer recommended as monotherapy for stroke prevention in atrial fibrillation; oral anticoagulants (warfarin or direct oral anticoagulants) are far more effective and have replaced aspirin in this indication. Aspirin may still be used in patients with concurrent established CAD on top of anticoagulation, but this combination markedly increases bleeding and is increasingly being de-escalated.

Back to Table of Contents

Key Research Papers

  1. Antithrombotic Trialists' Collaboration meta-analysis (BMJ 2002) — PubMed PMID 12096097
  2. ISIS-2 trial (Lancet 1988): aspirin in acute MI — PubMed PMID 2899772
  3. Physicians' Health Study (NEJM 1989): primary prevention foundation trial — PubMed PMID 2664509
  4. Women's Health Study (NEJM 2005): aspirin primary prevention in women — PubMed PMID 15753114
  5. ARRIVE trial (Lancet 2018): primary prevention in moderate-risk adults — PubMed PMID 30158069
  6. ASCEND trial (NEJM 2018): primary prevention in diabetes — PubMed PMID 30146931
  7. ASPREE trial (NEJM 2018): healthy older adults, no CV benefit — PubMed PMID 30221597
  8. ASPREE all-cause mortality finding (NEJM 2018) — PubMed PMID 30221596
  9. USPSTF 2022 aspirin primary prevention recommendation — PubMed PMID 35471505
  10. ACC/AHA 2019 primary prevention guideline — PubMed PMID 30894318
  11. CAPRIE trial (Lancet 1996): clopidogrel vs aspirin — PubMed PMID 8918275
  12. CURE trial (NEJM 2001): aspirin + clopidogrel in ACS — PubMed PMID 11519503
  13. ADAPTABLE trial (NEJM 2021): 81 mg vs 325 mg in secondary prevention — PubMed PMID 33999547
  14. Roth GJ & Majerus PW (J Clin Invest 1975): COX-1 acetylation mechanism — PubMed PMID 1206094
  15. Vane JR (Nat New Biol 1971): aspirin inhibits prostaglandin synthesis — PubMed PMID 5284360

Live PubMed Searches

  1. Aspirin secondary cardiovascular prevention
  2. Aspirin primary cardiovascular prevention
  3. Aspirin myocardial infarction
  4. Aspirin ischemic stroke
  5. Aspirin platelet thromboxane mechanism

Back to Table of Contents

Connections

Back to Table of Contents